Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa L Smith

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Food Microbiology|September 10, 2013
Photobleaching with phloxine B sensitizer to reduce food matrix interference for detection of Escherichia coli serotype O157:H7 in fresh spinach by flow cytometryDan A Buzatu, Willie M Cooper, Christine Summage-West, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemiaLeslie A Andritsos, Amy J Johnson, Gerard Lozanski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2019
Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell LymphomaFabienne Lucas, Kerry A Rogers, Bonnie K Harrington, et al.
Blood|September 6, 2008
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cellsRosa Lapalombella, Bo Yu, Georgia Triantafillou, et al.
Blood|December 8, 2009
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathwayRosa Lapalombella, Leslie Andritsos, Qing Liu, et al.
Blood|June 29, 2012
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridolEmilia Mahoney, David M Lucas, Sneha V Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic LeukemiaSarah E M Herman, Arnau Montraveta, Carsten U Niemann, et al.
Blood|December 7, 2013
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)Jennifer A Woyach, Engin Bojnik, Amy S Ruppert, et al.
Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
JAMA Oncology|July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaKami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Food Microbiology|September 10, 2013
Photobleaching with phloxine B sensitizer to reduce food matrix interference for detection of Escherichia coli serotype O157:H7 in fresh spinach by flow cytometryDan A Buzatu, Willie M Cooper, Christine Summage-West, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 23, 2008
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemiaLeslie A Andritsos, Amy J Johnson, Gerard Lozanski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2019
Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell LymphomaFabienne Lucas, Kerry A Rogers, Bonnie K Harrington, et al.
Blood|September 6, 2008
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cellsRosa Lapalombella, Bo Yu, Georgia Triantafillou, et al.
Blood|December 8, 2009
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathwayRosa Lapalombella, Leslie Andritsos, Qing Liu, et al.
Blood|June 29, 2012
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridolEmilia Mahoney, David M Lucas, Sneha V Gupta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2016
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic LeukemiaSarah E M Herman, Arnau Montraveta, Carsten U Niemann, et al.
Blood|December 7, 2013
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)Jennifer A Woyach, Engin Bojnik, Amy S Ruppert, et al.
Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
JAMA Oncology|July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaKami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.
Pageof 4